Home » Stocks » CHE

Chemed Corporation (CHE)

Stock Price: $548.17 USD 2.96 (0.54%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 8.72B
Revenue (ttm) 2.07B
Net Income (ttm) 271.29M
Shares Out 15.94M
EPS (ttm) 16.49
PE Ratio 33.25
Forward PE 28.25
Dividend $1.36
Dividend Yield 0.25%
Trading Day January 22
Last Price $548.17
Previous Close $545.21
Change ($) 2.96
Change (%) 0.54%
Day's Open 542.56
Day's Range 539.07 - 554.08
Day's Volume 59,363
52-Week Range 350.85 - 554.08

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 2 days ago

3 Outpatient Home Health Stocks Set to Ride the Industry's Upturn

Other stocks mentioned: DVA, USPH
CNBC Television - 2 weeks ago

Final Trades: CVS, Gold, Chemed & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other stocks mentioned: CVS, BILI, GLD
Zacks Investment Research - 3 weeks ago

DVA vs. CHE: Which Stock Is the Better Value Option?

Other stocks mentioned: DVA
Zacks Investment Research - 1 month ago

DVA vs. CHE: Which Stock Is the Better Value Option?

Other stocks mentioned: DVA
GuruFocus - 1 month ago

The sale of Uber Elevate may recoup some of the losses suffered in the effort to build a marketable air taxi

Other stocks mentioned: DECK, RELX
Zacks Investment Research - 1 month ago

DVA vs. CHE: Which Stock Is the Better Value Option?

Other stocks mentioned: DVA
Zacks Investment Research - 2 months ago

Chemed (CHE) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Investment Research - 2 months ago

Chemed (CHE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Forbes - 2 months ago

Many investors believe that financial markets react to the news. But it's a bit more nuanced than that.

Other stocks mentioned: BAH, CBOE, CL, KR
Business Wire - 2 months ago

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 34-cents per share on the Company's capital sto...

Zacks Investment Research - 2 months ago

DVA vs. CHE: Which Stock Is the Better Value Option?

Other stocks mentioned: DVA
Business Wire - 2 months ago

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the Credit Suisse 29th Annual Virtual Healthcare Conference on Tuesday, Novemb...

Zacks Investment Research - 2 months ago

Chemed (CHE) could produce exceptional returns because of its solid growth attributes.

Zacks Investment Research - 2 months ago

Chemed (CHE) reports solid revenue growth across key subsidiaries in third-quarter results.

Seeking Alpha - 2 months ago

Chemed Corporation (CHE) CEO Kevin McNamara on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Chemed (CHE) delivered earnings and revenue surprises of 21.80% and 2.17%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 2 months ago

Shares of Chemed (NYSE:CHE) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 40.46% year over year to $4.86, which beat the...

Business Wire - 2 months ago

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (Chemed) (NYSE:CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation's largest providers of end-of-life care, and Roto-Ro...

Zacks Investment Research - 2 months ago

Coronavirus is going to affect the earnings results of healthcare players. While hospitals and health insurers might have suffered the COVID-19 impact, others providing virtual care and COVID-...

Other stocks mentioned: CRL, DVA, NVCR, UHS
Zacks Investment Research - 3 months ago

Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 3 months ago

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE:CHE) today announced that it will release financial results for the third quarter ended September 30, 2020, on Thursday, October 29, 2020,...

Zacks Investment Research - 3 months ago

DVA vs. CHE: Which Stock Is the Better Value Option?

Other stocks mentioned: DVA
Forbes - 3 months ago

Nervous investors are bracing for a rough trading day amid news that President Trump and the first lady tested positive for COVID-19. Furthermore, markets faced additional headwinds based on t...

Other stocks mentioned: CACI, GLDD, TNET, TTEC
GuruFocus - 3 months ago

As the world grapples with an unprecedented coronavirus pandemic, five health care stocks that have outperformed the Standard & Poor's 500 Index by at least 5% in the year to date are Amerisou...

Other stocks mentioned: ABC, NEOG, NVO, RMD
Zacks Investment Research - 4 months ago

Chemed (CHE) reported earnings 30 days ago. What's next for the stock?

Forbes - 4 months ago

Markets are looking for some direction today with the Dow lower, the S&P flat, and the Nasdaq higher. Some optimism is shown on the economic side today with durable goods orders rising 11.2% i...

Other stocks mentioned: HI, JKHY, KDP, UI
Investors Business Daily - 5 months ago

Chemed shows rising price performance, earning an upgrade to its IBD Relative Strength Rating The post Stocks Generating Improved Relative Strength: Chemed appeared first on Investor's Busine...

Zacks Investment Research - 5 months ago

Amid the pandemic scenario, Chemed's (CHE) VITAS and Roto-Rooter both have been classified as essential services.

Seeking Alpha - 5 months ago

Chemed Corporation (CHE) CEO Kevin McNamara on Q2 2020 Results - Earnings Call Transcript

Forbes - 5 months ago

Consumer sentiment continues to slide as the count of coronavirus cases keeps increasing in the U.S., putting the economic recovery in doubt.

Other stocks mentioned: CSGS, LMT, PRSC, PWR
Zacks Investment Research - 5 months ago

Chemed (CHE) witnesses solid revenue growth across key subsidiaries in Q2 earnings.

Zacks Investment Research - 5 months ago

Chemed (CHE) delivered earnings and revenue surprises of 16.36% and -1.40%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 5 months ago

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-R...

Benzinga - 5 months ago

Chemed (NYSE:CHE) unveils its next round of earnings this Wednesday, July 29. Get prepared with Benzinga's ultimate preview for Chemed's Q2 earnings.

Forbes - 5 months ago

After a brief recovery in the early hours, all major indices are currently trading in the red. The rising COVID cases and a debated stimulus package could determine how markets behave in the w...

Other stocks mentioned: GD, HD, SAIC, WMS
Zacks Investment Research - 6 months ago

Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 6 months ago

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE:CHE) today announced that it will release financial results for the second quarter ended June 30, 2020, on Wednesday, July 29, 2020, follo...

Zacks Investment Research - 6 months ago

In the latest trading session, Chemed (CHE) closed at $467.36, marking a +1.62% move from the previous day.

Zacks Investment Research - 7 months ago

Chemed (CHE) closed the most recent trading day at $456.01, moving +1.3% from the previous trading session.

GuruFocus - 7 months ago

“The greatest companies in lousy industries share certain characteristics. They are low-cost operators and penny-pinchers in the executive suite.

Other stocks mentioned: ATRI, OFLX, ROL
Zacks Investment Research - 7 months ago

Chemed (CHE) closed at $456.38 in the latest trading session, marking a +0.92% move from the prior day.

Zacks Investment Research - 7 months ago

Debt financing is a feasible option as long as the companies succeed in generating a higher rate of return compared to the interest rate

Other stocks mentioned: SNPS, TNK, TSLA, WST
Zacks Investment Research - 7 months ago

Chemed (CHE) closed at $478.51 in the latest trading session, marking a -0.78% move from the prior day.

Zacks Investment Research - 7 months ago

Chemed (CHE) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 7 months ago

Investors continue to be optimistic about Chemed (CHE) on robust segmental growth.

Zacks Investment Research - 7 months ago

There are approximately 35 million Americans aged 65 or older currently and this number is expected to double in the next 25 years.

Other stocks mentioned: AMED, BKD, ENSG
Zacks Investment Research - 8 months ago

Is (CHE) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 8 months ago

Chemed (CHE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The Motley Fool - 8 months ago

These modern healthcare stocks could take care of you very well.

Other stocks mentioned: RCEL
Seeking Alpha - 8 months ago

Chemed Corporation (CHE) CEO Kevin McNamara on Q1 2020 Results - Earnings Call Transcript

About CHE

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates in two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned branches and independent contractors, and franchised locations. The company was incorporated in 1970 and is headquartered in Cincin... [Read more...]

Industry
Medical Care Facilities
CEO
Kevin McNamara
Employees
16,641
Stock Exchange
NYSE
Ticker Symbol
CHE
Full Company Profile

Financial Performance

In 2019, Chemed's revenue was $1.94 billion, an increase of 8.75% compared to the previous year's $1.78 billion. Earnings were $219.92 million, an increase of 7.00%.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Chemed stock is "Strong Buy." The 12-month stock price forecast is 580.00, which is an increase of 5.81% from the latest price.

Price Target
$580.00
(5.81% upside)
Analyst Consensus: Strong Buy